Moneycontrol PRO
you are here: HomeNewsIndia

Co-WIN: Minor glitches mar registrations as COVID-19 vaccination drive for general public kicks off

Co-WIN portal faced minor glitches as phase two of COVID-19 vaccination begins. Some people noted that they did not receive an OTP upon entering the mobile number as part of the registration process.

March 01, 2021 / 06:28 PM IST

The Co-WIN portal – – faced minor glitches on March 1, just as registration for the second phase of the nationwide vaccination drive commenced. Starting at 9.00 am, eligible beneficiaries were able to register on the Co-WIN 2.0 portal for immunisation.

Everyone above the age of 60 years and those over 45 years with comorbidities will be able to get the COVID-19 vaccine for free at government facilities and for a charge at a number of private hospitals. Private hospitals have been allowed to charge up to Rs 250 per dose of the COVID-19 vaccine.

Co-WIN, a digital platform, was created for real-time monitoring of COVID-19 vaccine delivery. The new version of the Co-WIN platform is GPS-enabled and beneficiaries will have the option to choose the inoculation session site both at the government and private facilities.

However, some people noted that they did not receive an OTP (one-time-password) upon entering the mobile number as part of the registration process. Some people said they received the OTP after a delay.

Some users were shown the message: "CoWIN server is facing issues. Please try later."


COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more

The Union Health Ministry also clarified that registration and booking of appointments will be done only through the Co-WIN portal and that there is no app for beneficiaries. The app on Play Store is only for administrators, the ministry said.

Screenshot of the Aarogya Setu app showing an "unexpected error" while registering in the Co-WIN section Screenshot of the Aarogya Setu app showing an "unexpected error" while registering in the Co-WIN section

Follow our LIVE blog for the latest updates of the coronavirus pandemic

More than 1.42 crore beneficiaries have received at least their first jabs as part of the two-dose regime.

As of February 28, India had recorded more than 1.1 crore confirmed COVID-19 cases, including 1.57 lakh deaths. A total of 1.07 crore patients had recuperated from the infectious disease. However, more than 1.64 lakh cases remained active across the country, comprising 1.48 percent of the total caseload. India's recovery rate stood at 96.1 percent even as many states were witnessing a resurgence in the number of cases being reported per day.

COVID-19 Vaccine Tracker: All you need to know about manufacturing and pricing

A speedy and efficient vaccination drive is being seen as the only main way to stop the spread of the disease and to restore normalcy in the pandemic-battered global economy.

In early January, India’s drug regulator had approved two vaccines - Covaxin developed by Bharat Biotech and Covishield from the Oxford/AstraZeneca stable being manufactured by the Serum Institute of India (SII) - for emergency use in the country. It is expected that more vaccine candidates will get emergency use approval in the coming months.

Click here for Moneycontrol’s full coverage of the coronavirus pandemic
Moneycontrol News
first published: Mar 1, 2021 09:48 am
ISO 27001 - BSI Assurance Mark